Doxorubicin News and Research

RSS
Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
Study shows GHRH antagonist's role in AML drug resistance

Study shows GHRH antagonist's role in AML drug resistance

ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage

ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage

Simple biomarkers offer early warning of hidden heart risk in childhood cancer survivors

Simple biomarkers offer early warning of hidden heart risk in childhood cancer survivors

Amino acid nanoparticles show promise for cancer treatment

Amino acid nanoparticles show promise for cancer treatment

Drug-eluting hydrogel has enhanced capabilities for treating hepatocellular carcinoma

Drug-eluting hydrogel has enhanced capabilities for treating hepatocellular carcinoma

Unraveling the immune system's response to nanoparticle drug delivery

Unraveling the immune system's response to nanoparticle drug delivery

Childhood cancer treatment linked to higher breast cancer risk

Childhood cancer treatment linked to higher breast cancer risk

ER-phagy alleviates drug-induced cardiomyopathy in cancer patients

ER-phagy alleviates drug-induced cardiomyopathy in cancer patients

Nanotechnology's triple threat: Advancing precision cancer treatment

Nanotechnology's triple threat: Advancing precision cancer treatment

High BMI increases risk of cardiotoxicity in breast cancer patients, study finds

High BMI increases risk of cardiotoxicity in breast cancer patients, study finds

Molecular insights into drug-induced GDF15 regulation in cancer cells and cardiomyocytes: implications for precision medicine

Molecular insights into drug-induced GDF15 regulation in cancer cells and cardiomyocytes: implications for precision medicine

Research paves the way to safer, more effective treatment for children with aggressive blood cancers

Research paves the way to safer, more effective treatment for children with aggressive blood cancers

A new platform for testing cancer drug toxicity

A new platform for testing cancer drug toxicity

Chemists discover novel, highly effective anticancer agents with tridimensional structures

Chemists discover novel, highly effective anticancer agents with tridimensional structures

Avacta appoints Karen Harrison as Chief Operating Officer for Therapeutics Division

Avacta appoints Karen Harrison as Chief Operating Officer for Therapeutics Division

Upgraded tumor model points the way toward more effective cancer therapies

Upgraded tumor model points the way toward more effective cancer therapies

UK oncologists and cardiologists collaborate to prevent chemo-induced cardiomyopathy in cancer patients

UK oncologists and cardiologists collaborate to prevent chemo-induced cardiomyopathy in cancer patients

Targeting newly discovered signaling pathway could boost the potency of cancer therapeutics

Targeting newly discovered signaling pathway could boost the potency of cancer therapeutics

DNA sequencing method detects where and how small molecule drugs interact with the targeted genome

DNA sequencing method detects where and how small molecule drugs interact with the targeted genome

Rare protein variant may hold the key to boosting effectiveness of breast cancer treatment

Rare protein variant may hold the key to boosting effectiveness of breast cancer treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.